TIDMSYNC
RNS Number : 4383H
Syncona Limited
03 August 2021
Syncona Limited
Result of Annual General Meeting and Retirement of Director
3 August 2021
At the Annual General Meeting of the Syncona Limited (the
"Company") held today, all Resolutions as set out in the 'Notice of
the 2021 Annual General Meeting' dated 1 July 2021 sent to
shareholders of the Company (the "Notice") were duly passed.
Resolutions 1 to 13 were proposed as Ordinary Resolutions.
Resolution 14 was proposed as a Special Resolution and Resolution
15 was proposed as an Extraordinary Resolution.
Details of the proxy voting results, which should be read
alongside the Notice, are noted below:
No Resolution For Discretion Against Abstain
(withheld)
Receive and consider
the Annual Audited
Financial Statements
of the Company for
the year ended 31
March 2021, together
with the Reports
of the Directors
1 and Auditors thereon 485,406,865 0 189,929 2,418
(9.96%) (0%) (0.04%)
-------------------------- ------------ ----------- -------------- ------------
Re-appointment of
Deloitte LLP (Guernsey
2 Branch) as Auditors 485,338,006 0 68,688 192,518
(99.99%) (0%) (0.01%)
-------------------------- ------------ ----------- -------------- ------------
Authorise the Directors
to determine the
remuneration of the
3 Auditors 485,591,907 0 7,305 0
(99.99%) (0%) (0.01%)
-------------------------- ------------ ----------- -------------- ------------
Re-elect Melanie 463,380,320
4 Gee as a Director (96.42%) 0 17,192,066 5,026,826
(0%) (3.58%)
-------------------------- ------------ ----------- -------------- ------------
Elect Virginia Holmes 485,588,541
5 as a Director (99.99%) 0 4,756 (0.01%) 5,915
(0%)
-------------------------- ------------ ----------- -------------- ------------
Re-elect Rob Hutchinson 485,552,870
6 as a Director (99.99%) 0 39,924 6,418
(0%) (0.01%)
-------------------------- ------------ ----------- -------------- ------------
Re-elect Nigel Keen 485,550,870
7 as a Director (99.99%) 0 41,924 6,418
(0%) (0.01%)
-------------------------- ------------ ----------- -------------- ------------
Re-elect Kemal Malik
8 as a Director 485,552,123 0 38,756 8,333
(99.99%) (0%) (0.01%)
-------------------------- ------------ ----------- -------------- ------------
Re-elect Nicholas
9 Moss as a Director 485,550,870 0 41,924 6,418
(99.99%) (0%) (0.01%)
-------------------------- ------------ ----------- -------------- ------------
Re-elect Gian Piero
10 Reverberi as a Director 485,554,038 0 38,756 6,418
(99.99%) (0%) (0.01%)
-------------------------- ------------ ----------- -------------- ------------
Approve the report
on implementation
of the Remuneration
Policy for Non-Executive 483,970,337 1,618,992
11 Directors (99.67%) 0 (0.33%) 9,883
(0%)
-------------------------- ------------ ----------- -------------- ------------
Authority to allot 1,464,359
12 and issue shares 484,125,810 0 (0.3%) 9,043
(99.7%) (0%)
-------------------------- ------------ ----------- -------------- ------------
Increase the maximum
aggregate amount
of fees for all the
Board collectively
in any financial
year from GBP500,000
13 to GBP1,000,000 468,468,131 0 16,378,940 752,141
(96.62%) (0%) (3.38%)
-------------------------- ------------ ----------- -------------- ------------
Authorise the Company
to purchase its own
14 shares 485,356,393 11,377 226,656 4,786
(99.94%) (0.01%) (0.05%)
-------------------------- ------------ ----------- -------------- ------------
Disapply pre-emption 485,561,682 11,377
15 rights (99.98%) (0.01%) 19,631 6,522
(0.01%)
-------------------------- ------------ ----------- -------------- ------------
A vote withheld is not a vote in law and has not been counted in
the votes for and against a resolution.
In addition, the Company confirms that, in line with the
announcement made previously, Tom Henderson has retired from the
Board of the Company with effect from the close of the AGM.
Melanie Gee, Chair of Syncona, commented:
"On behalf of the Board and all our stakeholders, I would like
to thank Tom for his significant contribution to both Syncona and
the Syncona Foundation over the last nine years. Tom was
instrumental in the creation of The Battle Against Cancer
Investment Trust (BACIT) in 2012, an innovative investment company
that persuaded underlying fund managers to provide their services
without charging a fee, and alongside that donated a percentage of
its net asset value each year to charity. Tom also played an
important role in BACIT's merger with Syncona Partners in 2016,
thereby forming the Syncona of today.
Tom remains the Chair of the Foundation, to which Syncona
continues to make significant donations, and we look forward to
continuing to benefit from his expertise and passion to support the
charities to which the Foundation donates and the individuals and
families that they support."
In accordance with the Listing Rule 9.6.2, a copy of all the
resolutions passed other than resolutions concerning ordinary
business have been submitted to the Financial Conduct Authority via
the National Storage Mechanism and will shortly be available for
inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism .
The full text of the resolutions can be found in the Notice,
which is available on the Company's website at
https://www.synconaltd.com/investors/shareholder-information/shareholder-documents/
.
Enquiries
Syncona Limited
Annabel Clay/Fergus Witt
Tel: +44 (0) 20 3981 7940
FTI Consulting
Ben Atwell / Natalie Garland-Collins / Tim Stamper
Tel: +44 (0) 20 3727 1000
Copies of this press release and other corporate information can
be found on the company website at: www.synconaltd.com.
About Syncona:
Syncona's purpose is to invest to extend and enhance human life.
We do this by founding, building and funding a portfolio of global
leaders in life science, to deliver transformational treatments to
patients in areas of high unmet need.
Our strategy is to found, build and fund companies around
exceptional science to create a dynamic portfolio of 15-20 globally
leading healthcare businesses for the benefit of all our
stakeholders. We focus on developing treatments for patients by
working in close partnership with world-class academic founders and
management teams. Our balance sheet underpins our strategy enabling
us to take a long-term view as we look to improve the lives of
patients with no or few treatment options, build sustainable life
science companies and deliver strong risk-adjusted returns to
shareholders.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGUPUGWRUPGGGW
(END) Dow Jones Newswires
August 03, 2021 07:32 ET (11:32 GMT)
Syncona (LSE:SYNC)
Historical Stock Chart
From Apr 2024 to May 2024
Syncona (LSE:SYNC)
Historical Stock Chart
From May 2023 to May 2024